INVESTIGATION OF CLINICAL AND HORMONAL EFFECTS OF SOMATOSTATIN ANALOGUE

生长抑素类似物的临床和激素效应研究

• 批准号: 6279342
• 负责人: MICHAEL O THORNER
• 金额: $ 3.19万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6279342
• 关键词: clinical research; drug screening /evaluation; endocrine neoplasm; endocrine pharmacology; hormone related neoplasm /cancer; hormone therapy; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; peptide hormone analog; somatostatin

This study will determine whether somatostatin analogue Sandoz 201-995 is effective in suppressing hormone secretion by aggressive hypersecretory endocrine tumors. The somatostatin analogue, octreotide, is admimistered to patients with various types of hypersecretory endocrine tumors to determine the suppressive effect of this drug on hormone hypersecretion. Twenty-seven patients with neuroendocrine tumors such as ectopic ACTH, growth hormone producing tumors, growth hormone releasing hormone tumors and a cranial hemangiopericytoma causing hypophosphatemia have been studied to date.

本研究将确定生长激素抑制素类似物Sandoz 201-995是否 有效抑制激素分泌， 高分泌性内分泌肿瘤生长抑素类似物奥曲肽， 适用于各种类型的高分泌性 内分泌肿瘤，以确定这种药物对 激素分泌过多 27例神经内分泌 肿瘤如异位ACTH、生长激素产生肿瘤、生长 激素释放激素瘤和颅内血管外皮细胞瘤 引起低磷酸盐血症的原因至今已被研究。